DOCSLIB.ORG

A Phase 2 Study of Filibuvir in Combination with Pegylated IFN Alfa and Ribavirin for Chronic HCV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Phase 2 Study of Filibuvir in Combination with Pegylated IFN Alfa and Ribavirin for Chronic HCV ORIGINAL ARTICLE July-August, Vol. 13 No. 4, 2014: 364-375 A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV Maribel Rodriguez-Torres,* Eric M. Yoshida,** Patrick Marcellin,*** Subasree Srinivasan,****, Vivek S. Purohit,**** Cunshan Wang,**** Jennifer L. Hammond**** * Fundación de Investigación and San Juan Bautista School of Medicine, San Juan, Puerto Rico, USA. ** University of British Columbia and Vancouver General Hospital, Vancouver, B.C. Canada. *** Service d’Hépatologie, Hôpital Beaujon, Université Paris-Diderot, Clichy, France. **** Pfizer, Global Innovative Pharma Business Unit, Groton, CT, and Collegeville, PA, USA. No longer affiliated with Pfizer. ABSTRACT Objectives. Filibuvir is a non-nucleoside inhibitor of hepatitis C virus (HCV) polymerase. This study evalua- ted the safety and efficacy of filibuvir plus pegylated interferon alfa-2a (pegIFN)/ribavirin. Material and methods. Treatment-naïve, HCV genotype-1 patients were randomized to receive filibuvir 300 or 600 mg twice daily (BID) or placebo plus pegIFN (180 μg/wk) and ribavirin (1,000/1,200 mg BID) for 24 weeks. Filibu- vir patients who achieved defined response through week 24 discontinued therapy at week 24. All other patients continued on open-label pegIFN/ribavirin through week 48. The primary endpoint was the propor- tion of patients who achieved sustained virologic response (SVR) defined as HCV RNA < 15 IU/mL at end of treatment (weeks 24 or 48) and week 72. Results. Overall, 288 patients were randomized and treated. SVR was achieved by 41.7, 39.6, and 45.8% of patients in the filibuvir 300 mg, 600 mg, and placebo arms, respec- tively. While the addition of filibuvir to pegIFN/ribavirin improved on-treatment virologic response parame- ters, this did not translate into improved SVR rates due to a high rate of virologic relapse following completion of therapy (300 mg: 35.9%; 600 mg: 42.9%; placebo: 25.4%). The most commonly reported adverse events were nausea, fatigue, headache, and insomnia, and were reported at similar rates across arms. Con- clusions. Filibuvir plus pegIFN/ribavirin did not improve the percentage of patients achieving SVR compared with administration of pegIFN/ribavirin alone. However, the agent was well tolerated and was associated with higher on-treatment virologic response parameters. Further evaluation of filibuvir in combination with other direct-acting antiviral agents may be considered. Key words. NS5B. Non-nucleoside inhibitor. Treatment naïve. Safety. Efficacy. INTRODUCTION studies in HCV-infected patients demonstrated a dose-dependent reduction in HCV RNA concentra- Filibuvir (FLV; Pfizer Inc, New York, NY, USA) tions following administration of FLV monotherapy is a non-nucleoside inhibitor (NNI) of the hepatitis for 7-10 days, with mean maximum reductions of > C virus (HCV) ribonucleic acid (RNA)-dependent 2.0 log10 IU/mL at doses ≥ 450 mg twice daily RNA polymerase. In vitro, FLV exhibits potent (BID).2 When administered in combination with activity against HCV polymerases and replicons de- pegylated interferon alfa-2a (pegIFN) and ribavirin rived from genotype 1 strains of HCV, with equipo- (RBV) for 4 weeks, a significant increase in the rate tent activity against the 1a and 1b subtypes.1 Initial of rapid virologic response (RVR) was observed compared with administration of pegIFN/RBV alone (60-75% vs. 0%, respectively); however, con- tinued follow-up of patients determined that the ini- Correspondence and reprint request: Jennifer L. Hammond, Ph.D. Pfizer Global Innovative Pharma Business Unit, 500 Arcola Road, Collegeville, tial response to FLV therapy did not translate into PA 19426, USA. higher rates of sustained virologic response (SVR), Tel.: +1 484 865 4094. Fax: +1 860 686 5542 and it was hypothesized this was due to the short E-mail: [email protected] duration of FLV administration.3 Manuscript received: March 26, 2014. The present study was conducted to determine Manuscript accepted: April 6, 2014. whether longer duration of FLV administered in 365 FLV plus pegIFN and RBV for HCV infection. , 2014; 13 (4): 364-375 combination with pegIFN/RBV would significantly Study design increase the proportion of patients who achieved SVR. This was a multicenter, multinational, double- Patients were randomized in a 1:1:1 ratio to receive blind, randomized, placebo-controlled Phase 2b FLV dosed at 300 or 600 mg BID or matching placebo study to assess the safety and efficacy of FLV dosed in combination with pegIFN/RBV, and were stratified at 300 or 600 mg BID in combination with pegIFN according to screening HCV RNA level (≤ 400,000 and RBV in treatment-naïve HCV genotype 1 infect- IU/mL or > 400,000 IU/mL) and by participation in a ed patients. semen sub-study. FLV or matching placebo was administered during the first 24 weeks of the study MATERIAL AND METHODS only. Those patients randomized to either of the FLV arms who achieved HCV RNA < 15 IU/mL by week 4 Patients and whose HCV RNA level remained < 15 IU/mL through week 24 discontinued all therapy at week 24. All patients provided written informed consent. All other patients continued on open-label pegIFN/ The study is registered with ClinicalTrials.gov RBV through week 48 (Figure 1). Patients and investi- (NCT00987337). The protocol and informed consent gators were unblinded to treatment assignment at forms were approved by independent ethics commit- week 24 to determine eligibility to discontinue therapy. tees at all study centers in accordance with national All patients had a screening visit up to 28 days procedures. The studies were conducted according to before the start of dosing; visits at baseline, weeks 2 the ethical principles in the Declaration of Helsinki4 and 4, and monthly visits thereafter through week and in compliance with all Good Clinical Practice 24. Patients who discontinued therapy at week 24 guidelines, local laws, and regulations. had follow-up visits at weeks 36, 48, and 72. Pa- Patients from 70 sites in North America (United tients who required therapy beyond week 24 contin- States and Canada), Europe (Belgium, France, ued to have monthly visits through week 48, and Germany, Hungary, and Spain), and Asia (Republic follow-up visits at weeks 60 and 72. of Korea) were screened for inclusion in the study. An independent data monitoring committee was Treatment-naïve (no prior treatment with IFN ± responsible for periodic assessments of safety and ef- RBV or investigational anti-HCV agents) male and ficacy data, and made recommendations concerning female patients aged ≥ 18 years were eligible for in- continuation, termination, or other modifications to clusion in the study. All patients were required to the trial based on the observed beneficial or adverse be HCV seropositive, infected with a genotype 1 effects of the treatment under study. All sponsor strain (VERSANT HCV Genotype 2.0 Assay, Inno- personnel responsible for the conduct of the trial, genetics, Ghent, Belgium), and have plasma HCV with the exception of the sponsor study program- RNA levels ≥ 10,000 IU/mL at screening. In addi- mer, remained blinded to the results provided to the tion, a non-cirrhotic fibrosis classification (i.e., data monitoring committee. Ishak score ≤ 4 or equivalent) from a liver biopsy obtained within 24 months of screening was re- Follow-up* quired for enrollment. FLV 300 mg + pegIFN/RBV Patients were excluded if they were co-infected pegIFN/RBV Follow-up with either HIV or hepatitis B, had evidence of se- Follow-up* vere or decompensated liver disease or liver disease FLV 600 mg + pegIFN/RBV unrelated to HCV infection, or had any pre-existing pegIFN/RBV Follow-up medical condition or laboratory abnormality that made them unsuitable for treatment with pegIFN/ Placebo + pegIFN/RBV pegIFN/RBV Follow-up RBV. Additional exclusion criteria included an ab- 0244872 normal electrocardiogram (ECG) suggestive of clini- Week cally significant cardiac disease or QTc > 450 ms at screening, and history of solid organ transplant, or Figure 1. Study schematic. *Patients randomized to either active alcohol or substance abuse sufficient to pre- of the FLV groups who achieved HCV RNA < 15 IU/mL by week vent adherence to study medication and/or follow- 4, and whose HCV RNA level remained < 15 IU/mL through week 24 discontinued all therapy at week 24. All other up. Lastly, female patients who were pregnant or patients continued on oped-label pegIFN/RBV through week nursing and male patients whose female partner was 48. FLV: filibuvir. pegIFN: pegylated interferon alfa-2a. RBV: pregnant were excluded. ribavirin. 366 Rodriguez-Torres M, et al. , 2014; 13 (4): 364-375 Stopping rules take FLV and RBV with food (at least a light meal). The use of clinically significant inhibitors of cyto- Patients who met the following criteria discon- chrome P450 (CYP) 3A4 or sensitive CYP3A4 sub- tinued FLV/placebo but were allowed to remain on strates was not permitted owing to the potential for pegIFN/RBV at the discretion of the investigator: uncharacterized interactions with FLV. The use of <1 log reduction in HCV RNA relative to baseline erythropoietin or granulocyte colony-stimulating by week 4; HCV RNA > 15 IU/mL at week 12; or factors to treat hematologic toxicities associated > 2 log increase in HCV RNA from nadir. Patients with pegIFN/RBV therapy was not permitted. who met any of the following criteria were required to discontinue all therapy (FLV/placebo, pegIFN, Dose rationale and RBV): < 2 log reduction in HCV RNA relative to baseline by week 12; HCV RNA > 15 IU/mL at FLV doses of 300 mg BID and 600 mg BID were se- week 24; two or more consecutive HCV RNA meas- lected based on an exposure response analysis of re- urements > 1,000 IU/mL following achievement of sults from a 10-day monotherapy study2 and results HCV RNA < 15 IU/mL.
Load more

Recommended publications
  • Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for Biomedical Research, Inc
    VIROLOGICA SINICA, August 2010, 25 (4):246-266 DOI 10.1007/s12250-010-3140-2 © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2010 Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for BioMedical Research, Inc. Cambridge, Massachusetts 02139, USA) Abstract: Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
    [Show full text]
  • Reviews in Basic and Clinical Gastroenterology
    GASTROENTEROLOGY 2010;138:447–462 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY REVIEWS IN BASIC AND CLINICAL John P. Lynch and David C. Metz, Section Editors GASTROENTEROLOGY Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection CHRISTOPH SARRAZIN and STEFAN ZEUZEM J. W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany Chronic hepatitis C virus (HCV) infection is one of agents that are also named specific, targeted antiviral the major causes of cirrhosis, hepatocellular carci- therapies (STAT-C) for HCV infection are in phase 1–3 noma, and liver failure that leads to transplantation. trials. We review resistance to DAA agents, focusing on The current standard treatment, a combination of compounds in development such as reagents that target pegylated interferon alfa and ribavirin, eradicates the the HCV nonstructural (NS)3 protease, the NS5A pro- virus in only about 50% of patients. Directly acting tein, and the RNA-dependent RNA polymerase NS5B. We antiviral (DAA) agents, which inhibit HCV replica- also discuss indirect inhibitors or compounds that in- tion, are in phase 1, 2, and 3 trials; these include hibit HCV replication by not yet completely resolved reagents that target the nonstructural (NS)3 protease, mechanisms, such as cyclophilin inhibitors, nitazox- the NS5A protein, the RNA-dependent RNA-polymer- anide, and silibinin (Table 1, Figure 1). ase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell Parameters That Affect Resistance proteins. Because of the high genetic heterogeneity of Heterogeneity of HCV HCV and its rapid replication, monotherapy with HCV has a high rate of turnover; its half-life was DAA agents poses a high risk for selection of resistant estimated to be only 2–5 hours, with the production and variants.
    [Show full text]
  • WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T (51) International Patent Classification: (74) Agent: PINO, Mark, J.; Connolly Bove Lodge & Hutz C07D 417/04 (2006.01) A61K 31/542 (2006.01) LLP, 1875 Eye Street, Nw, Suite 1100, Washington, DC C07D 513/04 (2006.01) A61P 31/14 (2006.01) 20006 (US). A61K 31/5415 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 12/032297 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 5 April 2012 (05.04.2012) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/472,286 6 April 201 1 (06.04.201 1) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US) : ANADYS (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC.
    [Show full text]
  • HCV Eradication with Direct Acting Antivirals (Daas)?
    HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d’Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. [email protected] HCV eradication with direct acting antivirals (DAAs)? HCV replication HCV genome and DAAs targets NS3 inhibitors NS5A inhibitors NS5B inhibitors Take home messages HCV viral cycle Asselah et al. Liver Int. 2015;35 S1:56-64. Direct acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir Direct Acting Antivirals: 2015 Asselah et al. Liver Int. 2015;35 S1:56-64. Genetic barrier for HCV direct acting antivirals High Nucleos(t)ide 1 mutation= high cost to Analog Inhibitors fitness, 2-3 additional mutations to increase fitness 2 st generation Protease Inhibitors n Non Nucleos(t)ide Analog Inhibitors : NS5 A Inhibitors 1 st generation Protease Inhibitors 1 mutation= low cost to fitness Low Halfon et al. J Hepatol 2011. Vol 55(1):192-206. HCV protease inhibitors (PI) Inhibit NS3/NS4A serine protease responsible for the processing of the polyprotein 1st generation 1st generation, 2nd wave 2nd generation Resistance low low high barrier Genotype activity 1: 1 a< 1b All except 3 all Drug drug Important Less Less interaction Drugs Boceprevir Simeprevir (Janssen) MK-5172 Telaprevir Faldaprevir (BI) ACH-2684 Paritaprevir (ABT-450)/r (AbbVie) Vedroprevir (Gilead) Vaniprevir (Merck) Sovaprevir (Achillion) Asunaprevir (BMS) NS3/NS4A structure Repositioning of helicase domain Self cleavage Lipid Bilayer Inactive Insertion of the Active carboxy-terminal tail Bartenschlager et al.
    [Show full text]
  • 2019 Icar Program & Abstracts Book
    Hosted by the International Society for Antiviral Research (ISAR) ND International Conference 32on Antiviral Research (ICAR) Baltimore MARYLAND PROGRAM and USA Hyatt Regency BALTIMORE ABSTRACTS May 12-15 2019 ND TABLE OF International Conference CONTENTS 32on Antiviral Research (ICAR) Daily Schedule . .3 Organization . 4 Contributors . 5 Keynotes & Networking . 6 Schedule at a Glance . 7 ISAR Awardees . 10 The 2019 Chu Family Foundation Scholarship Awardees . 15 Speaker Biographies . 17 Program Schedule . .25 Posters . 37 Abstracts . 53 Author Index . 130 PROGRAM and ABSTRACTS of the 32nd International Conference on Antiviral Research (ICAR) 2 ND DAILY International Conference SCHEDULE 32on Antiviral Research (ICAR) SUNDAY, MAY 12, 2019 › Women in Science Roundtable › Welcome and Keynote Lectures › Antonín Holý Memorial Award Lecture › Influenza Symposium › Opening Reception MONDAY, MAY 13, 2019 › Women in Science Award Lecture › Emerging Virus Symposium › Short Presentations 1 › Poster Session 1 › Retrovirus Symposium › ISAR Award of Excellence Presentation › PechaKucha Event with Introduction of First Time Attendees TUESDAY, MAY 14, 2019 › What’s New in Antiviral Research 1 › Short Presentations 2 & 3 › ISAR Award for Outstanding Contributions to the Society Presentation › Career Development Panel › William Prusoff Young Investigator Award Lecture › Medicinal Chemistry Symposium › Poster Session 2 › Networking Reception WEDNESDAY, MAY 15, 2019 › Gertrude Elion Memorial Award Lecture › What’s New in Antiviral Research 2 › Shotgun Oral
    [Show full text]
  • Polymerase Inhibitors
    New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14th - 15th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B NS5A NS3 Bifunctional NS5B RNA-dependent protease / helicase RNA polymerase Antiviral Activity of DAAs Vary Among and Within Classes 3-14 day monotherapy in genotype 1 patients NS3 protease inhibitors NS5A inhibitors non-nucleoside inhibitors nucleos/tide inhibitors Median or Mean HCV RNA Decline (log IU/mL) Median or Mean HCV RNA BCP, boceprevir; TVP, telaprevir. Sarrazin C, Zeuzem S. Gastroenterology. 2010;138:447-62. Characteristics of DAAs and HTAs Efficacy Genotype Barrier to independency resistance NS3/4A (protease inhibitors) +++ ++ + - ++ NS5A +++ + - ++ + - ++ NS5B (nucleosides) + - +++ +++ +++ NS5B (non-nucleosides) + - ++ + + Cyclophilin Inhibitors ++ +++ +++ Nucleosidic polymerase inhibitors • RG-7128 (Mericitabine): moderate efficacy, safe • GS-7977 (Sofosbuvir): high efficacy, safe • Alios-2200 = VX135: high efficacy, early phase 2 • NM-283 (Valopicitabine): low efficacy, GI toxicity > • R-1626: moderate efficacy, lymphopenia > • INX-189 = BMS-986094: high efficacy, cardiac tox. > • IDX-184: moderate efficacy, on hold • PSI-938: high efficacy, hepatotoxicity > Nucleosidic polymerase inhibitors • RG-7128 (Mericitabine): moderate efficacy, safe • GS-7977 (Sofosbuvir): high efficacy, safe • Alios-2200 = VX135: high efficacy, early phase 2 • NM-283 (Valopicitabine): low efficacy, GI toxicity > • R-1626: moderate efficacy, lymphopenia > • INX-189 = BMS-986094: high efficacy, cardiac tox. > • IDX-184: moderate efficacy, on hold • PSI-938: high efficacy, hepatotoxicity > PROPEL study: Efficacy and safety of MCB + PR in G1/4 treatment-naive patients . Mericitabine nucleoside analog MCB 500 mg 12 wk (RVR-guided) polymerase inhibitor 100 MCB 1000 mg 8 wk (RVR-guided) MCB 1000 mg 12 wk (RVR-guided) .
    [Show full text]
  • Review Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV RNA-Dependent RNA Polymerase
    Antiviral Therapy 2012; 17:411–423 (doi: 10.3851/IMP2088) Review Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase Jean-Michel Pawlotsky1,2*, Isabel Najera3, Ira Jacobson4 1National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France 2INSERM U955, Créteil, France 3Roche, Nutley, NJ, USA 4Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA *Corresponding author e-mail: [email protected] Mericitabine (RG7128), an orally administered prodrug passage experiments. To date, no evidence of genotypic of PSI-6130, is the most clinically advanced nucleoside resistance to mericitabine has been detected by popula- analogue inhibitor of the RNA-dependent RNA poly- tion or clonal sequence analysis in any baseline or on- merase (RdRp) of HCV. This review describes what has treatment samples collected from >600 patients enrolled been learnt so far about the resistance profile of mericit- in Phase I/II trials of mericitabine administered as mon- abine. A serine to threonine substitution at position 282 otherapy, in combination with pegylated interferon/ (S282T) of the RdRp that reduces its replication capacity ribavirin, or in combination with the protease inhibitor, to approximately 15% of wild-type is the only variant danoprevir, for 14 days in the proof-of-concept study of that has been consistently generated in serial in vitro interferon-free therapy. Introduction The approval of boceprevir and telaprevir [1,2], the first HCV variants are selected and grow when the inter- inhibitors of the non-structural (NS) 3/4A (NS3/4A) feron response is inadequate [3,4,6].
    [Show full text]
  • A8121014 Public Disclosure Synopsis
    Public Disclosure Synopsis Protocol A8121014 – 10 October 2014 – Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME and COMPOUND NUMBER: Filibuvir / PF-00868554 PROTOCOL NO.: A8121014 PROTOCOL TITLE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Filibuvir Plus Pegylated Interferon Alfa-2a and Ribavirin in Treatment Naïve, HCV Genotype 1 Infected Subjects Study Centers: A total of 65 centers participated in the study and enrolled subjects, including 23 centers in the United States; 8 centers in Spain; 7 centers each in Canada, France, and Germany; 6 centers in Belgium; 4 centers in Hungary; and 3 centers in the Republic of Korea. Study Initiation and Final Completion Dates: 10 November 2009 to 27 January 2012 Phase of Development: Phase 2 Study Objectives: Primary Objective: To determine if the addition of filibuvir to a regimen of pegylated interferon-α (pegIFN)/ ribavirin (RBV) increased the proportion of subjects who achieved a sustained viral response (SVR) at the end of study compared to pegIFN/RBV alone Secondary Objectives: To determine if filibuvir in combination with pegIFN/RBV increased the proportion of subjects who achieved undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) concentrations at study Weeks 4, 12, 24, and 48 (Path 2 only) compared to pegIFN/RBV therapy alone To determine if the addition of filibuvir to a regimen of pegIFN/RBV increased
    [Show full text]
  • Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis
    Review Article Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis Debajit Dey and Manidipa Banerjee* Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India Abstract When such inflammation, as manifested in symptoms such as jaundice, nausea, abdominal pain, malaise etc, is caused Viral hepatitis remains a significant worldwide threat, in spite by viral infections, the condition is referred to as viral hepatitis.1 of the availability of several successful therapeutic and vacci- Five hepatotropic viruses – named hepatitis A, B, C, D and nation strategies. Complications associated with acute and E viruses – target liver cells in humans and cause acute and chronic infections, such as liver failure, cirrhosis and hepato- chronic hepatitis. In addition, other viruses such as the cellular carcinoma, are the cause of considerable morbidity adenovirus, cytomegalovirus (CMV) and Epstein-Barr virus and mortality. Given the significant burden on the healthcare (EBV), occasionally cause symptoms of hepatitis.2 system caused by viral hepatitis, it is essential that novel, While an acute infection in healthy, immunocompetent more effective therapeutics be developed. The present review individuals is cleared spontaneously, complications like cir- attempts to summarize the current treatments against viral rhosis, hepatocellular carcinoma (HCC) and fulminant hepatic hepatitis, and provides an outline for upcoming, promising failure (FHF) may arise in immunocompromised individuals, new therapeutics. Development of novel therapeutics requires due to associated secondary reasons such as existing infec- an understanding of the viral life cycles and viral effectors in tions, alcohol abuse, or genetic predisposition.1,3 HCC, the molecular detail. As such, this review also discusses virally- third leading cause of cancer-related deaths worldwide,4 is encoded effectors, found to be essential for virus survival closely associated with hepatitis B virus (HBV) infections.
    [Show full text]
  • Structural & Functional Characterization of the Dengue Virus Non
    This document is downloaded from DR‑NTU (https://dr.ntu.edu.sg) Nanyang Technological University, Singapore. Structural & functional characterization of the dengue virus non‑structural protein 5 (NS5) Soh, Sherryl Tingjin 2018 Soh, S. T. (2018). Structural & functional characterization of the dengue virus non‑structural protein 5 (NS5). Doctoral thesis, Nanyang Technological University, Singapore. http://hdl.handle.net/10356/73218 https://doi.org/10.32657/10356/73218 Downloaded on 06 Oct 2021 23:07:19 SGT STRUCTURAL & FUNCTIONAL CHARACTERIZATION OF THE DENGUE VIRUS NON-STRUCTURAL PROTEIN 5 (NS5) SOH TINGJIN SHERRYL SCHOOL OF BIOLOGICAL SCIENCES 2017 STRUCTURAL & FUNCTIONAL CHARACTERIZATION OF THE DENGUE VIRUS NON-STRUCTURAL PROTEIN 5 (NS5) SOH TINGJIN SHERRYL School of Biological Sciences A thesis submitted to the Nanyang Technological University in partial fulfilment of the requirement for the degree of Doctor of Philosophy 2017 Acknowledgements Acknowledgements First and foremost, I would like to express my deepest gratitude to both my supervisors, Associate Professor Julien Lescar in NTU and Dr Lim Siew Pheng in Novartis Institute for Tropical Diseases (NITD), for their continuous guidance, encouragement and intense patience throughout my graduate education. Their expertise, meticulous attention and support had been greatly beneficial to me and to the success of my project. I am grateful to my colleagues in NITD, especially Ms Seh Cheah Chen and Dr Shan Chao who generously shared their knowledge and provided me with ample support and assistance. I would also like to thank my colleagues in NTU, especially Dr El Sahili Abbas and Ms Grace Chan Kar Yarn, who had rendered me with extensive help and advices for my crystallography experiments in NTU.
    [Show full text]
  • Mechanisms of Substrate Recognition by HCV NS3/4A Protease Provide Insights Into Drug Resistance: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2011-05-31 Mechanisms of Substrate Recognition by HCV NS3/4A Protease Provide Insights Into Drug Resistance: A Dissertation Keith P. Romano University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry, Biophysics, and Structural Biology Commons, Chemical Actions and Uses Commons, Digestive System Diseases Commons, Pharmaceutical Preparations Commons, Therapeutics Commons, Virology Commons, Virus Diseases Commons, and the Viruses Commons Repository Citation Romano KP. (2011). Mechanisms of Substrate Recognition by HCV NS3/4A Protease Provide Insights Into Drug Resistance: A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/2bmp-kp97. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/554 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. MECHANISMS OF SUBSTRATE RECOGNITION BY HCV NS3/4A PROTEASE PROVIDE INSIGHTS INTO DRUG RESISTANCE A Dissertation Presented By Keith Patrick Romano Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 31, 2011 Biochemistry and Molecular Pharmacology MECHANISMS OF SUBSTRATE RECOGNITION BY HCV NS3/4A PROTEASE PROVIDE INSIGHTS INTO DRUG RESISTANCE A Dissertation Presented By Keith Patrick Romano The signatures of the Dissertation Defense Committee signify completion and approval as to style and content of the Dissertation.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]